ACE inhibitors in arterial hypertension treatment among various clinical groups
Abstract
The classification of angiotensin-converting enzyme (ACE) inhibitors is presented. The use of these medications in various clinical situations is discussed, including chronic heart failure, coronary heart disease, metabolic syndrome, diabetes mellitus, renal pathology, myocardial hypertrophy, proteinuria / microalbuminuria, and cerebrovascular disease. Drug interaction and tolerability aspects of ACE therapy are also discussed.
About the Authors
O. D. OstroumovaRussian Federation
M. L. Maksimov
Russian Federation
References
1. Руководство по артериальной гипертонии. Под ред. Е.И. Чазова, И.Е. Чазовой. М.: Медиа Медика 2005; 784 с.
2. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваск тер профил 2008; 7(6), приложение 2: 5-31.
3. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. Circulation 1994; 90: 1731-8.
4. Torp-Pedersen C, Kober L for the TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left ventricular function after acute myocardial infarction. Lancet 1999; 354: 9-12.
5. Pitt B, O’Neill B, Feldman R et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inchibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058-63.
6. HOPE study investigators. Effect of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
7. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваск тер профил 2008; 7(6), приложение 4: 4-40.
8. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease; randomized, double0blind, placebo-controlled, multicentre trial (EUROPA study). Lancet 2003; 362: 782-8.
9. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
10. Диагностика и лечение метаболического синдрома. Российские рекомендации (второй пересмотр). Кадиоваск тер профил 2009; 8(6), приложение 2: 3-28.
11. Vrablík M, Freiberger T, Lánská V, Češka R on behalf of the Project Investigators. The ATRACTIV Project: Improved Cardiovascular Prevention in the Context of Primary Care in the Czech Republic. Vnitř Lék 2008; 54(12): 871-8.
12. Hansson L, Lindholm LH, Niskanen L. Captopril Preventional Trial. Lancet 1999; 353: 611-6.
13. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-convertion enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. Circulation 2001; 104: 1248-54.
14. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Кардиоваск тер профил 2008; 7(6), приложение 3: 5-19.
15. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
Review
For citations:
Ostroumova O.D., Maksimov M.L. ACE inhibitors in arterial hypertension treatment among various clinical groups. Cardiovascular Therapy and Prevention. 2010;9(7):90-96.
Email this article 
